Characteristic	Intervention(s) and comparator(s)	Sex [female %]	Age [mean/range years (SD), or as reported]	FBG [mg/dl]	BP systolic/diastolic [mm Hg]	BMI [mean kg/m2]	Co‐medications / Co‐interventions	Co‐morbidities
Kaats 1996	I1: CrP 200 μg/day	‐	45.9 ± 11.9	‐	‐	30.3 ± 5.5	‐	‐
	I2: CrP 400 μg/day	‐	45.7 ± 11.8	‐	‐	30.6 ± 5.1	‐	‐
	C: placebo	‐	44.3 ± 11.2	‐	‐	30.6 ± 5.5	‐	‐
Kaats 1998	I: CrP 400 μg/day	‐	41.1 ± 10.5	‐	‐	30.2 ± 7.1	‐	‐
	C: placebo	‐	43.5 ± 7.6	‐	‐	28.4 ± 5.4	‐	‐
Joseph 1999	I: CrP 1000 μg/day + resistance training	47.1	63 ± 4	5.73 ± 0.43 mmol/L	‐	28.9 ± 2.5	Control diet + resistance training	‐
	C: placebo + resistance training	46.7	60 ± 4	5.73 ± 0.43 mmol/L	‐	29.3 ± 2.4	Control diet + resistance training	‐
Kleefstra 2006	I1: CrP 500 μg/day	86.2	60 ± 8.8	‐	147 ± 24 / 85 ± 10	35 ± 7.2	Insulin	‐
	I2: CrP 1000 μg/day	84.9	59 ± 6.4	‐	156 ± 25 / 84 ± 14	33 ± 4.2	Insulin	‐
	C: placebo	83.1	62 ± 7.5	‐	159 ± 20 / 83 ± 10	34 ± 4.3	Insulin	‐
Iqbal 2009	I: CrP 500 μg/day	60.6	47.7 ± 10	4.74 ± 0.8 mmol/L	130 ± 12 / 81 ± 10	37.8 ± 9	Insulin	‐
	C: placebo	30.0	51.1 ± 13	4.54 ± 0.6 mmol/L	129 ± 15 / 79 ± 10	35.2 ± 6	Insulin	‐
Volpe 2001	I: CrP 400 μg/day + weight training	100	42.6 ± 6.5	42.6 ± 6.5	91 ± 13	27‐41	Weight training	‐
	C: placebo + weight training	100	42.5 ± 4.2	42.5 ± 4.2	91 ± 6	27‐41	Weight training	‐
Anton 2008	I: CrP 400 μg/day	0	32 ± 10.2	87.1 ± 1.4	115 ± 13 / 74 ± 10	30.7 ± 4.2	Control diet	‐
	C: placebo	0	34.5 ± 9.7	87.9 ± 6.8	114 ± 11 / 74 ± 10	31.9 ± 4.7	Control diet	‐
Campbell 1999	I: CrP 1000 μg/day + resistance training	0	50‐75	‐	‐	27‐34	Resistance training	‐
	C: placebo + resistance training	0	50‐75	‐	‐	27‐34	Resistance training	‐
Yazaki 2010	I: CrP 400 μg/day	50	25‐75	‐	133 ± 17 / 80 ± 10	36.0 ± 6.7	‐	‐
	C: placebo	50	25‐75	‐	137 ± 18 / 81 ± 11	36.1 ± 7.6	‐	‐
Footnotes "‐" denotes not reported "±" denotes single standard deviation BP: blood pressure; BMI: body mass index; C: control; CrP: chromium picolinate; FBG: fasting blood glucose; I: intervention